June 17, 2008 - AstraZeneca (NYSE: AZN) and Columbia University Medical Center announced that they have entered into a strategic research collaboration in metabolic related diseases, to develop novel therapeutics primarily in type 2 diabetes and obesity and, with a secondary focus on atherosclerosis (hardening of the arteries)/dyslipidemia (abnormal blood lipid levels).The preclinical and clinical research will focus on discovering mechanisms and identifying new biological targets for intervention that have the potential of being starting points for successful and commercially viable treatments to tackle these diseases that are major risk factors for cardiovascular morbidity and mortality... AstraZeneca's Press Release -
